Barclays PLC Collegium Pharmaceutical, Inc Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Barclays PLC holds 73,703 shares of COLL stock, worth $2.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,703

Previous 79,754 7.59%

Holding current value

$2.13 Million

Previous $2.29 Million 3.76%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$28.04 - $33.91 $169,670 - $205,189	-6,051 Reduced 7.59%	73,703 $2.2 Million
Q4 2024 Feb 13, 2025	BUY	$28.61 - $41.86 $134,524 - $196,825	4,702 Added 6.26%	79,754 $2.29 Million
Q3 2024 Nov 15, 2024	BUY	$31.4 - $39.07 $1.42 Million - $1.77 Million	45,291 Added 152.18%	75,052 $2.9 Million
Q2 2024 Aug 14, 2024	SELL	$31.36 - $39.99 $545,758 - $695,945	-17,403 Reduced 36.9%	29,761 $958,000
Q1 2024 May 15, 2024	SELL	$31.23 - $40.91 $798,488 - $1.05 Million	-25,568 Reduced 35.15%	47,164 $1.83 Million
Q4 2023 Feb 15, 2024	BUY	$21.16 - $30.8 $701,221 - $1.02 Million	33,139 Added 83.7%	72,732 $2.24 Million
Q3 2023 Nov 07, 2023	BUY	$21.23 - $24.28 $121,286 - $138,711	5,713 Added 16.86%	39,593 $886,000
Q2 2023 Aug 03, 2023	SELL	$21.06 - $24.0 $16,195 - $18,456	-769 Reduced 2.22%	33,880 $728,000
Q1 2023 May 04, 2023	BUY	$23.0 - $29.88 $101,821 - $132,278	4,427 Added 14.65%	34,649 $831,000
Q4 2022 Feb 13, 2023	BUY	$16.14 - $23.55 $62,720 - $91,515	3,886 Added 14.76%	30,222 $701,000
Q3 2022 Nov 03, 2022	SELL	$15.46 - $20.1 $232,008 - $301,640	-15,007 Reduced 36.3%	26,336 $423,000
Q2 2022 Aug 12, 2022	SELL	$14.22 - $20.88 $109,252 - $160,421	-7,683 Reduced 15.67%	41,343 $732,000
Q1 2022 May 16, 2022	SELL	$17.2 - $22.5 $405,318 - $530,212	-23,565 Reduced 32.46%	49,026 $998,000
Q4 2021 Feb 14, 2022	SELL	$17.5 - $21.35 $202,457 - $246,998	-11,569 Reduced 13.75%	72,591 $1.36 Million
Q3 2021 Nov 09, 2021	BUY	$17.75 - $25.39 $599,009 - $856,836	33,747 Added 66.94%	84,160 $1.66 Million
Q2 2021 Aug 13, 2021	SELL	$21.74 - $25.28 $504,998 - $587,229	-23,229 Reduced 31.54%	50,413 $1.19 Million
Q1 2021 May 13, 2021	BUY	$19.25 - $26.1 $1.2 Million - $1.63 Million	62,394 Added 554.71%	73,642 $1.75 Million
Q4 2020 Feb 11, 2021	SELL	$17.83 - $22.29 $81,073 - $101,352	-4,547 Reduced 28.79%	11,248 $225,000
Q3 2020 Nov 12, 2020	SELL	$15.78 - $20.82 $49,501 - $65,312	-3,137 Reduced 16.57%	15,795 $328,000
Q2 2020 Aug 12, 2020	BUY	$15.49 - $23.51 $124,771 - $189,373	8,055 Added 74.06%	18,932 $331,000
Q1 2020 May 13, 2020	SELL	$13.89 - $25.45 $295,634 - $541,677	-21,284 Reduced 66.18%	10,877 $178,000
Q4 2019 Feb 10, 2020	BUY	$10.7 - $22.24 $82,957 - $172,426	7,753 Added 31.76%	32,161 $662,000
Q3 2019 Nov 14, 2019	BUY	$10.16 - $13.28 $21,417 - $27,994	2,108 Added 9.45%	24,408 $280,000
Q2 2019 Aug 14, 2019	SELL	$10.62 - $16.59 $313,895 - $490,350	-29,557 Reduced 57.0%	22,300 $293,000
Q1 2019 May 15, 2019	BUY	$13.58 - $18.72 $192,157 - $264,888	14,150 Added 37.53%	51,857 $786,000
Q4 2018 Feb 14, 2019	BUY	$14.78 - $19.68 $394,448 - $525,219	26,688 Added 242.2%	37,707 $648,000
Q3 2018 Nov 14, 2018	BUY	$14.16 - $24.3 $66,679 - $114,428	4,709 Added 74.63%	11,019 $162,000
Q2 2018 Aug 14, 2018	SELL	$21.79 - $28.29 $96,900 - $125,805	-4,447 Reduced 41.34%	6,310 $150,000
Q1 2018 May 15, 2018	BUY	$18.15 - $29.21 $103,690 - $166,876	5,713 Added 113.26%	10,757 $276,000
Q4 2017 Feb 14, 2018	BUY	$9.3 - $19.14 $42,017 - $86,474	4,518 Added 858.94%	5,044 $93,000
Q3 2017 Nov 14, 2017	BUY	$9.15 - $11.97 $4,812 - $6,296	526	526 $6,000

Others Institutions Holding COLL

# of Institutions

255

Shares Held

37.2M

Call Options Held

61.1K

Put Options Held

5.8K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $985M
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account